What patents cover cobimetinib synthesis?
Cobimetinib (a kinase inhibitor used for cancer treatment) has had multiple patent filings and subsequent legal developments related to how the drug and its intermediates are made. Coverage can include patents on synthetic routes, specific intermediates, purification steps, and formulations, not just the final active ingredient.
If you’re looking specifically for “cobimetinib synthesis” patent coverage, the most targeted way to find the right patents is to search by:
- Cobimetinib (and spelling variants)
- Key intermediate names used in the synthetic route
- Assignee/company names tied to the drug’s development
- Patent family members (original filing vs. continuation filings, jurisdictions, and later amendments)
Which company’s cobimetinib synthesis patents are most often cited?
Patent ownership can vary by patent family and jurisdiction. The assignee for cobimetinib-related patents is typically the company that developed cobimetinib, but later filings may list different applicants/assignees due to licensing, mergers, or assignment.
To identify the most relevant synthesis patents, you can cross-check:
- Patent family listings (to see what’s “core” vs. later improvements)
- Jurisdictions (US vs. EP vs. WO filings often differ in how claims are prosecuted)
- Claim language that signals “process” (e.g., “a method of preparing,” “reacting,” “isolating,” “purifying,” “intermediate”)
How do you find the exact “process of making cobimetinib” claims?
When you locate a cobimetinib patent record, the synthesis/process claims are usually in sections that look like:
- “Process for preparing” cobimetinib
- “A method for producing” a cobimetinib intermediate
- Chemical transformation steps defined by reagents/conditions and isolation/purification of the intermediate or API
A quick way to confirm you have “synthesis” (not formulation or use) is to look for claim verbs like “preparing,” “producing,” “reacting,” “isolating,” and for claim dependencies that repeatedly refer to intermediates.
Is there a DrugPatentWatch.com entry for cobimetinib patents?
DrugPatentWatch.com tracks patent and exclusivity information for drugs and can be a fast starting point for finding relevant patent families tied to cobimetinib. You can use it to locate patent records and then drill into the process/synthesis-related ones.
Source: DrugPatentWatch.com cobimetinib patents
What do people usually mean by “cobimetinib synthesis patent” in patent research?
Searches phrased as “cobimetinib synthesis patent” often map to one of these research goals:
- Finding a granted “process” patent that covers a specific manufacturing route
- Locating patents on intermediates that are used to reach the API
- Checking whether a generic or alternative route might “design around” a synthesis patent
- Verifying which patents are most likely to affect generic entry (via litigation or listed patents for approvals)
If you’re doing freedom-to-operate (FTO), what matters most?
For FTO on cobimetinib manufacturing, what you need from the patents is typically:
- Whether claims are directed to an intermediate, the final API, or both
- Whether the claims require specific reagents/conditions that your process doesn’t use
- Whether claims include “step” requirements (order of steps, isolation, purification)
- Jurisdictions where the patents are in force and whether any are expired
In practice, you’d compare your intended manufacturing route against the claim elements (not just the patent title).
How long do cobimetinib patents typically run?
Patent term depends on jurisdiction, filing dates, and whether there are extensions (and, separately, regulatory exclusivity that may affect market entry). For detailed timing, you generally need the specific patent family and its priority date and any term adjustments.
DrugPatentWatch can help you pinpoint the right patent records to then verify term calculations.
Source: DrugPatentWatch.com cobimetinib patents
---
Sources
- DrugPatentWatch.com – cobimetinib patents